Quiz: What Agent Does ASCO Recommend for Frontline Stage IV Lung Cancer Treatment?
What single agent does the new ASCO guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer without positive markers but with high PD-L1 expression? Is there an age limit for use of SBRT for early-stage lung cancer? Test your knowledge in our latest quiz.
Is there an age limit for use of stereotactic body radiation therapy (SBRT) for early-stage lung cancer? What single agent does the new American Society of Clinical Oncology (ASCO) guideline recommend for first-line treatment of patients with stage IV non-small-cell lung cancer (NSCLC) without positive markers but with high programmed death ligand 1 (PD-L1) expression? Test your knowledge in our latest quiz.
Question 1
Answer and Question 2 on Next Page »
Answer
D.Pembrolizumab
According to the ASCO guideline, if a patient has low PD-L1 expression, standard chemotherapy should be offered. For second-line treatment, single-agent atezolizumab, nivolumab, or pembrolizumab may be used if the first-line regimen did not contain immune checkpoint therapy. Crizotinib is recommended for patients with ROS1 gene rearrangement who received no prior crizotinib therapy.
Question 2
Answer and Question 3 on Next Page »
Answer
A. 3%
According to the report, the median age of the patients was 62 years; the majority (71%) were never smokers and presented with advanced disease at diagnosis. Median survival for the 12 patients who received HER2-targeted therapies was 2.1 years vs 1.4 years for the 12 patients who did not (P = .48). The authors noted that “HER2-directed therapies should be investigated in this subgroup of patients.”
Question 3
Answer and Question 4 on Next Page »
Answer
D. Recent smokers
Recent smokers had a hazard ratio (HR) of 0.38 (P P P = .0208 and HR, 1.62; P = .236) and never smokers (HR, 1.025; P = .971 and HR, 1.33; P = .638), respectively. “Sequencing data revealed that mutational burden was not associated with veliparib benefit,” the study concluded.
Question 4
Answer and Question 5 on Next Page »
Answer
A. Median overall survival was similar between both arms
The study authors concluded, “The addition of palifosfamide to carboplatin and etoposide failed to improve survival in early-stage SCLC.” Serious adverse events did not differ significantly between the two arms.
Question 5
Answer
A. Higher rate of grade 3 or higher pneumonitis
The grade 3 or higher pneumonitis rate was 1.3% vs 1.6% vs 1.5% (P = 1.0) in patients aged
Quiz: Best Second-Line Tx for Metastatic Lung SCC and Crohn Disease?
March 1st 2018Are there special second-line considerations for an SCC lung patient with a history of Crohn disease who progressed on first-line carboplatin and gemcitabine? Can any pretreatment tests be deferred for a patient with a history of heavy smoking and a single solitary nodule found on his CT chest scan? Take this multiquestion quiz to find out.
Quiz: Are EGFR Mutations and ALK Rearrangements in Lung Cancer Mutually Exclusive?
February 1st 2018Know when to change targeted therapies in patients with progressive lung cancer? How about appropriate patient criteria for segmentectomy or wedge resection? Test your knowledge in our latest quiz.
